Bluebird Bio | BLUE - Actif À Court Terme



Actif À Court Terme Changement Date
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 29.06B 1.17B 2025-12
Arrowhead Research USD 1.17B 223.75M 2025-12
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Moderna USD 6.54B 54M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Tectonic Therapeutic USD 257.36M 15.88M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12